📊 MD Key Takeaways
Is Pediatrix Medical Group, Inc. (MD) a Good Investment?
Pediatrix Medical Group faces severe operational and financial headwinds: negative operating cash flow of -$129.8M indicates the company is burning cash despite reported profitability, while revenue declined 4.9% YoY with net income flat. Returns on equity (3.4%) and assets (1.4%) are critically low, signaling structural business challenges in a competitive healthcare staffing market.
Why Buy Pediatrix Medical Group, Inc. Stock? MD Key Strengths
- Moderate leverage with 0.45x debt-to-equity ratio provides some balance sheet flexibility
- Adequate cash reserves of $205.8M provide near-term liquidity buffer
- Still generating positive net income of $29.6M despite operational challenges
MD Stock Risks: Pediatrix Medical Group, Inc. Investment Risks
- Negative operating cash flow of -$129.8M is unsustainable and indicates core business deterioration
- Revenue contraction of 4.9% YoY signals declining market demand or competitive pressures
- Weak interest coverage ratio of 2.0x leaves limited margin for error if earnings decline further
- Critically low ROE (3.4%) and ROA (1.4%) suggest poor capital efficiency and asset utilization
- Rising shares outstanding risk if EPS gains (263% YoY) are from buybacks masking weak fundamentals
Key Metrics to Watch
- Operating cash flow trend and path to positive FCF generation
- Revenue stabilization and organic growth trajectory
- Return on equity improvement and working capital efficiency
- Debt service coverage ratio and interest coverage capacity
- Quarterly cash burn rate and cash runway sustainability
Pediatrix Medical Group, Inc. (MD) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Pediatrix Medical Group, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
MD Profit Margin, ROE & Profitability Analysis
MD vs Healthcare Sector: How Pediatrix Medical Group, Inc. Compares
How Pediatrix Medical Group, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Pediatrix Medical Group, Inc. Stock Overvalued? MD Valuation Analysis 2026
Based on fundamental analysis, Pediatrix Medical Group, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Pediatrix Medical Group, Inc. Balance Sheet: MD Debt, Cash & Liquidity
MD Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Pediatrix Medical Group, Inc.'s revenue has shown modest growth of 5% over the 5-year period. The most recent EPS of $-0.73 indicates the company is currently unprofitable.
MD Revenue Growth, EPS Growth & YoY Performance
MD Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $458.4M | $20.7M | $0.24 |
| Q3 2025 | $492.9M | $4.0M | $0.23 |
| Q2 2025 | $468.8M | $4.0M | $0.46 |
| Q1 2025 | $458.4M | $4.0M | $0.05 |
| Q3 2024 | $506.6M | $4.0M | $0.23 |
| Q2 2024 | $500.6M | $4.0M | $0.34 |
| Q1 2024 | $491.0M | $4.0M | $0.05 |
| Q3 2023 | $489.9M | $14.2M | $0.26 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Pediatrix Medical Group, Inc. Dividends, Buybacks & Capital Allocation
MD SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Pediatrix Medical Group, Inc. (CIK: 0000893949)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MD
What is the AI rating for MD?
Pediatrix Medical Group, Inc. (MD) has an AI rating of SELL with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are MD's key strengths?
Claude: Moderate leverage with 0.45x debt-to-equity ratio provides some balance sheet flexibility. Adequate cash reserves of $205.8M provide near-term liquidity buffer.
What are the risks of investing in MD?
Claude: Negative operating cash flow of -$129.8M is unsustainable and indicates core business deterioration. Revenue contraction of 4.9% YoY signals declining market demand or competitive pressures.
What is MD's revenue and growth?
Pediatrix Medical Group, Inc. reported revenue of $476.2M.
Does MD pay dividends?
Pediatrix Medical Group, Inc. does not currently pay dividends.
Where can I find MD SEC filings?
Official SEC filings for Pediatrix Medical Group, Inc. (CIK: 0000893949) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MD's EPS?
Pediatrix Medical Group, Inc. has a diluted EPS of $0.36.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MD a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Pediatrix Medical Group, Inc. has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MD stock overvalued or undervalued?
Valuation metrics for MD: ROE of 3.4% (sector avg: 15%), net margin of 6.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MD stock in 2026?
Our dual AI analysis gives Pediatrix Medical Group, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MD's free cash flow?
Pediatrix Medical Group, Inc.'s operating cash flow is $-129.8M, with capital expenditures of N/A. FCF margin is -27.3%.
How does MD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 6.2% (avg: 12%), ROE 3.4% (avg: 15%), current ratio 1.33 (avg: 2).